Congress Wealth Management LLC DE Buys 21,532 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Congress Wealth Management LLC DE grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 27.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,986 shares of the medical instruments supplier’s stock after purchasing an additional 21,532 shares during the quarter. Congress Wealth Management LLC DE owned approximately 0.44% of LeMaitre Vascular worth $6,569,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LMAT. SRS Capital Advisors Inc. raised its position in shares of LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares during the period. Personal CFO Solutions LLC lifted its stake in LeMaitre Vascular by 6.4% in the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 336 shares during the last quarter. KLR Investment Advisors LLC bought a new position in shares of LeMaitre Vascular during the 4th quarter worth approximately $351,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of LeMaitre Vascular by 18.6% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 6,342 shares of the medical instruments supplier’s stock valued at $421,000 after purchasing an additional 993 shares during the last quarter. Finally, Riverwater Partners LLC increased its holdings in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 198 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO George W. Lemaitre sold 68,906 shares of LeMaitre Vascular stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 87,431 shares of company stock worth $6,627,520. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded down $1.72 on Monday, reaching $80.56. 175,641 shares of the company’s stock were exchanged, compared to its average volume of 123,525. The company has a market capitalization of $1.81 billion, a P/E ratio of 53.35, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $84.15. The firm’s 50-day moving average is $76.81 and its two-hundred day moving average is $66.90.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. During the same period last year, the business earned $0.27 EPS. LeMaitre Vascular’s quarterly revenue was up 13.6% compared to the same quarter last year. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on LMAT shares. JMP Securities boosted their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their target price for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, June 22nd. Roth Mkm reaffirmed a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. Finally, Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.